Skip to main content

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Publication ,  Journal Article
Tepper, J; Krasna, MJ; Niedzwiecki, D; Hollis, D; Reed, CE; Goldberg, R; Kiel, K; Willett, C; Sugarbaker, D; Mayer, R
Published in: J Clin Oncol
March 1, 2008

PURPOSE: The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although primary radiation therapy with concurrent chemotherapy produces similar results. As both have curative potential, there has been great interest in the use of trimodality therapy. To this end, we compared survival, response, and patterns of failure of trimodality therapy to esophagectomy alone in patients with nonmetastatic esophageal cancer. PATIENTS AND METHODS: Four hundred seventy-five eligible patients were planned for enrollment. Patients were randomly assigned to either esophagectomy with node dissection alone or cisplatin 100 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 4 days on weeks 1 and 5 concurrent with radiation therapy (50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection. RESULTS: Fifty-six patients were enrolled between October 1997 and March 2000, when the trial was closed due to poor accrual. Thirty patients were randomly assigned to trimodality therapy and 26 were assigned to surgery alone. Patient and tumor characteristics were similar between groups. Treatment was generally well tolerated. Median follow-up was 6 years. An intent-to-treat analysis showed a median survival of 4.48 v 1.79 years in favor of trimodality therapy (exact stratified log-rank, P = .002). Five-year survival was 39% (95% CI, 21% to 57%) v 16% (95% CI, 5% to 33%) in favor of trimodality therapy. CONCLUSION: The results from this trial reflect a long-term survival advantage with the use of chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support trimodality therapy as a standard of care for patients with this disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 1, 2008

Volume

26

Issue

7

Start / End Page

1086 / 1092

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophagectomy
  • Esophageal Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., … Mayer, R. (2008). Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 26(7), 1086–1092. https://doi.org/10.1200/JCO.2007.12.9593
Tepper, Joel, Mark J. Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E. Reed, Richard Goldberg, Krystyna Kiel, Christopher Willett, David Sugarbaker, and Robert Mayer. “Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.J Clin Oncol 26, no. 7 (March 1, 2008): 1086–92. https://doi.org/10.1200/JCO.2007.12.9593.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086–92.
Tepper, Joel, et al. “Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.J Clin Oncol, vol. 26, no. 7, Mar. 2008, pp. 1086–92. Pubmed, doi:10.1200/JCO.2007.12.9593.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 1;26(7):1086–1092.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

March 1, 2008

Volume

26

Issue

7

Start / End Page

1086 / 1092

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Fluorouracil
  • Female
  • Esophagectomy
  • Esophageal Neoplasms